Related Experiment Video
Updated: Jul 17, 2025

Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
Published on: December 7, 2018
VEGF, IGF-1 and FGF-2 Serum Levels in Children and Adolescents with Autism Spectrum Disorder with and without Bipolar
Gokce Guldiken1, Ali Karayagmurlu2, Canan Kucukgergin3
1Health Ministry of Turkish Republic Reyhanlı State Hospital, Hatay, Turkey. drgokceguldiken@gmail.com.
Insights
Serum levels of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) were higher in children with autism spectrum disorder (ASD) and bipolar disorder (BD). These growth factors may serve as potential biomarkers for BD in young individuals with ASD.
Area of Science:
- Neuroscience
- Biochemistry
- Pediatrics
Background:
- Autism spectrum disorder (ASD) and bipolar disorder (BD) are complex neurodevelopmental conditions.
- Co-occurrence of ASD and BD presents unique diagnostic and management challenges in children and adolescents.
- Identifying reliable biomarkers is crucial for early diagnosis and effective treatment.
Purpose of the Study:
- To investigate serum levels of vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and fibroblast growth factor 2 (FGF-2).
- To explore the relationship between these growth factors and clinical characteristics in children and adolescents with ASD, with and without comorbid BD.
- To assess the potential of these factors as biomarkers for BD in the ASD population.
Main Methods:
- A study group of 40 subjects with ASD and BD was compared to a control group of 40 subjects with ASD.
- Serum samples were analyzed for VEGF, IGF-1, and FGF-2 using enzyme-linked immunosorbent assay (ELISA) kits.
- Clinical characteristics, including ASD severity, self-harming behavior, sleep disturbance, and BD episode history, were assessed.
Main Results:
- The ASD + BD group exhibited significantly higher ASD severity, self-harming behavior, and sleep disturbances compared to the ASD-only group.
- Serum levels of VEGF and FGF-2 were significantly elevated in the ASD + BD group versus the ASD group.
- No significant difference in IGF-1 levels was observed; however, VEGF correlated negatively with age at BD diagnosis, and IGF-1 correlated positively with the number of bipolar episodes.
Conclusions:
- Elevated serum VEGF and FGF-2 may indicate potential biomarkers for bipolar disorder in young individuals with autism spectrum disorder.
- These findings suggest that VEGF and FGF-2 could aid clinicians in diagnosing and monitoring BD in this specialized pediatric population.
- Further research is warranted to confirm the utility of VEGF and FGF-2 as clinical biomarkers for managing comorbid BD in children and adolescents with ASD.
Purpose:
To investigate serum levels of VEGF, IGF-1 and FGF-2, and relationships with several clinical characteristics in children and adolescents with autism spectrum disorder (ASD) with and without bipolar disorder (BD).
Method:
40 subjects with ASD + BD as study group, and 40 subjects with ASD as control group were included. Serum levels of VEGF, IGF-1, and FGF-2 were measured using commercial enzyme-linked immunosorbent assay kits.
Results:
The study group was significantly higher than the control group in terms of ASD severity, self-harming behavior and sleep disturbance. Serum VEGF and FGF-2 levels were significantly higher in the ASD + BD group than in the control group. There was no significant difference in serum IGF-1 levels between the two groups. There was no correlation between VEGF, IGF-1 and FGF-2 serum levels and ASD severity in the study group. However there was a negative correlation between VEGF levels and age at first diagnosis of BD, and a positive correlation between IGF-1 levels and the number of bipolar episodes in the study group.
Conclusion:
Growth factors like VEGF and FGF-2 may be potential biomarkers of bipolar disorder in young subjects with ASD. Given the difficulty of clinical management of BD in young subjects with ASD, potential biomarkers would help clinicians in the diagnosis and follow up of BD in this special population. Further research is needed whether VEGF and FGF-2 can be potential biomarkers in the clinical management of young subjects with ASD and BD.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Bipolar Disorder
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...

